Ionis Pharmaceuticals, Inc. IONS
Composite 32/100; the shares have moved about 47% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 6/100 — a strong mark against it.
Growth ranks 90/100 — a strong point in its favour.
Valuation ranks 6/100 — a strong mark against it. Quality ranks 10/100 — a strong mark against it. Momentum ranks 14/100 — a strong mark against it.
What the company does Ionis Pharmaceuticals discovers and commercializes RNA-targeted therapies. Its marketed drugs include SPINRAZA for SMA, WAINUA for ATTRv-PN, and QALSODY for ALS, with several candidates in late-stage trials such as olezarsen for SHTG and zilganerse for Alexander disease.
Key financials Ionis posts negative profitability metrics: ROE -68%, ROA -7%, ROCE -9%, gross margin 11%, operating margin -48%, net margin -31%. Revenue grew 87% but EPS fell 43% year-over-year. Liquidity is strong with a current ratio of 7.89, though leverage is high at debt/equity 5.50.
Stock health Momentum is weak: -29% over 3m, -35% over 6m, with RSI at 28.20 indicating oversold conditions. The stock is -39% below its 52-week high, but the Sideravia composite score is 33/100, flagging “poor quality, richly valued.”
Price vs fair value The stock trades at a discount of 70.42% versus the analyst 12-month target of 90.80. - Q2 2026 revenue beat and reiterated guidance (Zacks) - Q2 earnings call highlighted robust pipeline progress (GuruFocus.com) - Comparable biotech names like Biogen showed resilience post-earnings (Barrons.com) - Negative profitability and high valuation multiples (EV/EBITDA 135.77, P/B 19.02)
Looking forward Late-stage catalysts include Phase 3 readouts for olezarsen and zilganerse. Analysts expect continued revenue growth, but execution risks remain given negative margins and high cash burn. Pipeline progress and potential label expansions will be key drivers.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.